Ken Griffin Amphastar Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amphastar Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 226,775 shares of AMPH stock, worth $5.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

226,775

Previous 292,345 22.43%

Holding current value

$5.91 Million

Previous $6.71 Million 9.97%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$20.62 - $30.81 $1.35 Million - $2.02 Million	-65,570 Reduced 22.43%	226,775 $6.04 Million
Q2 2025 Aug 14, 2025	BUY	$22.96 - $28.29 $3.13 Million - $3.86 Million	136,366 Added 87.43%	292,345 $6.71 Million
Q1 2025 May 15, 2025	BUY	$26.24 - $38.48 $408,451 - $598,979	15,566 Added 11.09%	155,979 $4.52 Million
Q4 2024 Feb 14, 2025	BUY	$36.84 - $53.4 $190,683 - $276,398	5,176 Added 3.83%	140,413 $5.21 Million
Q3 2024 Nov 14, 2024	SELL	$36.99 - $50.09 $4.73 Million - $6.41 Million	-127,914 Reduced 48.61%	135,237 $6.56 Million

Q2 2024 Aug 14, 2024	BUY	$38.65 - $43.48 $7.55 Million - $8.5 Million	195,454 Added 288.72%	263,151 $10.5 Million
Q1 2024 May 15, 2024	SELL	$42.85 - $63.45 $2.08 Million - $3.08 Million	-48,502 Reduced 41.74%	67,697 $2.97 Million
Q4 2023 Feb 14, 2024	SELL	$44.49 - $62.93 $556,836 - $787,631	-12,516 Reduced 9.72%	116,199 $7.19 Million
Q3 2023 Nov 14, 2023	SELL	$45.51 - $65.0 $2.24 Million - $3.2 Million	-49,235 Reduced 27.67%	128,715 $5.92 Million
Q2 2023 Aug 14, 2023	BUY	$35.77 - $58.38 $5.24 Million - $8.56 Million	146,609 Added 467.79%	177,950 $10.2 Million
Q1 2023 May 15, 2023	SELL	$27.99 - $37.92 $312,536 - $423,414	-11,166 Reduced 26.27%	31,341 $1.18 Million
Q4 2022 Feb 14, 2023	SELL	$27.93 - $31.27 $3.71 Million - $4.15 Million	-132,758 Reduced 75.75%	42,507 $1.19 Million
Q3 2022 Nov 14, 2022	BUY	$27.56 - $37.75 $3.69 Million - $5.05 Million	133,867 Added 323.37%	175,265 $4.93 Million
Q2 2022 Aug 15, 2022	SELL	$29.79 - $42.29 $5.85 Million - $8.31 Million	-196,485 Reduced 82.6%	41,398 $1.44 Million
Q1 2022 May 16, 2022	BUY	$22.96 - $36.45 $559,328 - $887,958	24,361 Added 11.41%	237,883 $8.54 Million
Q4 2021 Feb 14, 2022	BUY	$18.14 - $23.29 $3.87 Million - $4.97 Million	213,522 New	213,522 $4.97 Million
Q3 2021 Nov 15, 2021	SELL	$17.83 - $21.49 $434,570 - $523,775	-24,373 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$17.11 - $20.92 $257,608 - $314,971	-15,056 Reduced 38.19%	24,373 $491,000
Q1 2021 May 17, 2021	SELL	$17.21 - $20.65 $528,501 - $634,140	-30,709 Reduced 43.78%	39,429 $722,000
Q4 2020 Feb 16, 2021	BUY	$17.76 - $21.24 $287,072 - $343,323	16,164 Added 29.95%	70,138 $1.41 Million
Q3 2020 Nov 16, 2020	BUY	$17.99 - $22.22 $292,049 - $360,719	16,234 Added 43.02%	53,974 $1.01 Million
Q2 2020 Aug 14, 2020	SELL	$14.25 - $22.46 $690,768 - $1.09 Million	-48,475 Reduced 56.23%	37,740 $848,000
Q1 2020 May 15, 2020	BUY	$12.66 - $20.08 $1.09 Million - $1.73 Million	86,215 New	86,215 $1.28 Million
Q4 2019 Feb 14, 2020	SELL	$17.07 - $20.64 $2.25 Million - $2.73 Million	-132,053 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$19.12 - $22.62 $1.43 Million - $1.69 Million	74,767 Added 130.52%	132,053 $2.62 Million
Q2 2019 Aug 14, 2019	BUY	$18.92 - $22.96 $815,943 - $990,172	43,126 Added 304.56%	57,286 $1.21 Million
Q1 2019 May 15, 2019	SELL	$19.46 - $25.28 $347,438 - $451,349	-17,854 Reduced 55.77%	14,160 $0
Q4 2018 Feb 14, 2019	SELL	$17.72 - $22.51 $38,381 - $48,756	-2,166 Reduced 6.34%	32,014 $637,000
Q1 2018 May 11, 2018	BUY	$17.23 - $20.35 $588,921 - $695,563	34,180 New	34,180 $641,000

Others Institutions Holding AMPH

# of Institutions

263

Shares Held

33.5M

Call Options Held

73.4K

Put Options Held

12.6K

View Full List

About Amphastar Pharmaceuticals, Inc.

Ticker AMPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,015,200
Market Cap $1.28B
Description
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-count...

More about AMPH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account